Evidence map›Paper›PMID 39362260›Full record

ReviewThe Lancet. Oncology2024

Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO).

Zachary S Zumsteg, Siddharth Sheth, Salma K Jabbour, Krishnan R Patel, Randall J Kimple, Terence M Williams, Meng Xu-Welliver, Pedro A Torres-Saavedra, Arta M Monjazeb, Jyoti Mayadev and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zachary S ZumstegDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: zachary.zumsteg@cshs.org.
Siddharth ShethDivision of Oncology, University of North Carolina, Chapel Hill, NC, USA.
Salma K JabbourDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Krishnan R PatelRadiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
Randall J KimpleDepartment of Human Oncology, Univeristy of Wisconsin, Madison, WI, USA.
Terence M WilliamsDepartment of Radiation Oncology, City of Hope, Duarte, CA, USA.
Meng Xu-WelliverDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Pedro A Torres-SaavedraDivision of Cancer Treatment and Diagnosis, Biometric Research Program, National Institutes of Health, Bethesda, MD, USA.
Arta M MonjazebDepartment of Radiation Oncology, University of California, San Diego, CA, USA.
Jyoti MayadevDepartment of Radiation Medicine and Applied Sciences, University of California, San Diego, CA, USA.
Steven E FinkelsteinThe US Oncology Network, Florida Cancer Affiliates, Panama City, FL, USA; Sarah Cannon Research Institute, Nashville, TN, USA; Associated Medical Professional of NY, US Urology Partners, Syracuse, NY, USA.
John M BuattiDepartment of Radiation Oncology, University of Iowa, Iowa City, IA, USA.
Sandip P PatelDivision of Medical Oncology, University of California, San Diego, CA, USA.
Steven H LinDepartment of Thoracic Radiation Oncology, Division of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
NCI NIH HHS U10 CA180868
6 · The paper itself

Abstract

NRG Oncology's Developmental Therapeutics and Radiation Therapy Subcommittee assembled an interdisciplinary group of investigators to address barriers to successful early phase clinical trials of novel combination therapies involving radiation. This Policy Review elucidates some of the many challenges associated with study design for early phase trials combining radiotherapy with novel systemic agents, which are distinct from drug-drug combination development and are often overlooked. We also advocate for potential solutions that could mitigate or eliminate some of these barriers, providing examples of specific clinical trial designs that could help facilitate efficient and effective evaluation of novel drug-radiotherapy combinations.

Indexed as

ChemoradiotherapyNeoplasmsSocieties, MedicalAnimalsAntineoplastic AgentsBiomarkers, TumorClinical Trials as TopicDrug DiscoveryDrug InteractionsHumansNeoplasm StagingAntineoplastic AgentsBiomarkers, Tumor

Identifiers

PMID39362260
PMCPMC11778933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.